Cargando…
Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
BACKGROUND: Denosumab (DMB) is a bone antiresorptive agent used to treat osteoporosis or metastatic cancer of the bones. However, denosumab-associated osteonecrosis of the jaw (DRONJ) has become a common complication in cancer patients. The prevalence of osteonecrosis of the jaw (ONJ) in cancer pati...
Autores principales: | Kang, Ji-Yeon, Kim, Sang-Yup, Lim, Jae-Seok, Kim, Jwa-Young, Jin, Ga-Youn, Lee, Yeon-Jung, Lee, Eun-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313599/ https://www.ncbi.nlm.nih.gov/pubmed/37389685 http://dx.doi.org/10.1186/s40902-023-00391-9 |
Ejemplares similares
-
Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019) -
Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022) -
Leiomyosarcoma of the jaw: case series
por: Choi, Yong-Suk, et al.
Publicado: (2020) -
Prediction models for early diagnosis of actinomycotic osteomyelitis of the jaw using machine learning techniques: a preliminary study
por: Choi, Sun-Gyu, et al.
Publicado: (2022) -
Improvement of Giant Cell Lesions of the Jaw Treated With High and Low Doses of Denosumab: A Case Series
por: Kim, Tara S, et al.
Publicado: (2017)